Get the Stockscreener App
2.91
1.02%
-0.03
Pre-market:
2.82
-0.09
-3.09%
Sonoma Pharmaceuticals Inc stock is traded at $2.91, with a volume of 14,414.
It is down -1.02% in the last 24 hours and down -9.35% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$2.94
Open:
$2.96
24h Volume:
14,414
Relative Volume:
0.01
Market Cap:
$5.35M
Revenue:
$12.31M
Net Income/Loss:
$-5.08M
P/E Ratio:
-3.0957
EPS:
-0.94
Net Cash Flow:
$-5.20M
1W Performance:
-1.36%
1M Performance:
-9.35%
6M Performance:
+6.59%
1Y Performance:
-23.34%
1-Day Range:
$2.8555
$2.96
1-Week Range:
$2.8001
$3.05
52-Week Range:
$1.75
$9.374
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
2.91 | 5.35M | 12.31M | -5.08M | -5.20M | -0.94 |
|
RGC
Regencell Bioscience Holdings Ltd
|
22.95 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
157.77 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.49 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.08 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.09 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
Global Dental Market Set to Reach USD 19.13 Bn by 2032, Driven by 7.5% CAGR | Coherent Market Insights - newstrail.com
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | SNOA Stock News - GuruFocus
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results - ACCESS Newswire
Sonoma Pharmaceuticals, Inc. SEC 10-K Report - TradingView
SONOMA PHARMACEUTICALS Earnings Preview: Recent $SNOA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Passes Above 200-Day Moving Average – Time to Sell? - Defense World
Dental Market Set to Witness Robust Growth Fueled by Aesthetic - openPR.com
Keloid Treatment Market Exclusive Trends Analysis with Forecast to 2034 - openPR.com
Pre-market Movers: NIVF, TRAW, KKR, AGEN... - RTTNews
Hospital Surgical Disinfectants Market Is Booming So Rapidly - openPR.com
Williams-Sonoma, Inc. (NYSE:WSM) Given Consensus Rating of “Hold” by Analysts - Defense World
Scar Treatment Market Is Booming So Rapidly | Merz, Lumenis, Sientra - newstrail.com
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above 200-Day Moving Average – Time to Sell? - Defense World
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - Business Wire
Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Sonoma Biotherapeutics Appoints Rajesh Krishnan, Ph.D., as Chief Technical Officer - citybiz
Keloid Treatment Market Development Accelerated by Consumer - openPR.com
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
Sonoma Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Checking in on Sonoma Pharmaceuticals Inc (SNOA) after recent insiders movement - knoxdaily.com
A Piece Of The Puzzle Missing From Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) 35% Share Price Climb - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Stocks of Sonoma Pharmaceuticals Inc (SNOA) are poised to climb above their peers - Sete News
Sonoma Pharmaceuticals (SNOA) Expands Acne Product Line to UK Re - GuruFocus
Sonoma Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
Financial Analysis: Integra Resources Corp (ITRG)’s Ratios Unveil Key Insights - DWinneX
Metric Deep Dive: Understanding Sonoma Pharmaceuticals Inc (SNOA) Through its Ratios - DWinneX
Analyzing SNOA’s price-to-book ratio for the last quarter - uspostnews.com
Crude Oil Falls Over 3%; Philip Morris Earnings Top Views - Benzinga
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results - Benzinga
Sonoma Pharmaceuticals Inc (SNOA) Stock: A Year of Declines and Increases - investchronicle.com
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX
UK Retail Deal Sparks Early Buying Frenzy in Pharma Stock - The Globe and Mail
Daily Progress: 60 Degrees Pharmaceuticals Inc (SXTP) Drop -15.51, Closing at 2.67 - DWinneX
Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Sonoma Pharmaceuticals Poised to Sell Acne Products in UK; Shares Soar Premarket - marketscreener.com
Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Cross Above 200-Day Moving Average – Here’s Why - Defense World
Sonoma Pharmaceuticals (SNOA) Expands Reach with UK Product Regi - GuruFocus
Major UK Retail Breakthrough: Sonoma's Natural Acne Treatment to Roll Out Across 1,200 Leading Pharmacies - Stock Titan
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $315.58 - Defense World
North America Scar Treatment Market Deep Research Report with - openPR.com
NovoCure (NASDAQ:NVCR) vs. Sonoma Pharmaceuticals (NASDAQ:SNOA) Financial Review - Defense World
Rising Trends of Scar Treatment Market in Worldwide | Top most Key - openPR.com
Analyzing Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) and Sonoma Pharmaceuticals (NASDAQ:SNOA) - Defense World
SNOA stock touches 52-week low at $1.84 amid market challenges - Investing.com Australia
SNOA stock touches 52-week low at $1.84 amid market challenges By Investing.com - Investing.com South Africa
Head to Head Survey: DarioHealth (NASDAQ:DRIO) & Sonoma Pharmaceuticals (NASDAQ:SNOA) - Defense World
Delaware passes law designed to stop more Elon Musks from leaving state - Yahoo Finance
Fast-paced Momentum Stock Sonoma Pharmaceuticals (SNOA) Is Still Trading at a Bargain - Yahoo Finance
Sonoma Pharmaceuticals expands agreement with WellSpring By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):